Merck ( MRK ) recently moved its Alzheimer’s disease candidate, MK-8931, into a phase II/III study (EPOCH). The study will evaluate the safety and efficacy of MK-8931, an oral β-amyloid
Excerpt from:
Merck’s Alzheimer’s Drug Progresses – Analyst Blog